Introduction: Intravenous (IV) iron replacement is an established treatment for iron deficiency and is recommended in various medical guidelines, but cheaper oral iron formulations remain first‐line therapy in several instances. Data on adherence to current prescription standards are lacking in Switzerland.Methods: Retrospective single center quality control study evaluating the appropriateness of IV iron replacement in 400 inpatients during 2019 and 2021 at a Swiss tertiary care hospital. Appropriateness of IV iron was assessed by expert chart review according to national and international guidelines.Results: IV iron prescriptions were assessed as inappropriate in 147 (37%) of cases (indication lacking in 13%, oral route preferred in 24%). Inappropriate prescribing was more common (p < .001) in surgical wards (66%) compared to medical units (48%) and the gynecologic ward (19%). Iron studies were lacking in 29% of inappropriate IV administrations. Insufficient replacement dosages were chosen in 38% of patients with appropriate prescription.Conclusion: Based on current guidelines, inappropriate in‐hospital prescription of IV iron was frequently observed. Considerable differences exist between hospital units, which are consistent with conflicting recommendations of professional societies. We recommend increased attention toward the prescription quality to avoid unnecessary, expensive, and potentially harmful use of IV iron.
Torque teno virus (TTV) is a recognized marker of immune competence, but its relevance in severe bacterial infections is unclear. We evaluated prevalence, viral load, and clinical relevance of TTV viremia in complicated Staphylococcus aureus infection (CSAI). In this ancillary analysis of two prospective pharmacokinetic cohort studies at a Swiss university hospital, stored plasma samples were tested for TTV DNA using TTV R‐GENE PCR, and cytokines were measured by multiplex immunoassay. Associations between TTV load, inflammatory biomarkers, and clinical outcomes (including 30‐day mortality) were assessed. Among 103 patients (median age 67.9 years; 85% with bloodstream infection), TTV viremia was detected in 76% at baseline with a median viral load of 2.85 log 10 copies/mL (IQR 1.87–3.56). Levels remained stable over 1 week despite declining inflammatory markers. Baseline TTV load was numerically higher in 30‐day non‐survivors (3.53 vs. 2.83 log 10 copies/mL; p = 0.054) and not associated with mortality after adjusting for age, sex, and SOFA score (OR 1.29 per log 10 increase; 95% CI 0.82–2.02; p = 0.268). TTV load was not associated with ICU admission, bacteremia duration, or length of stay. TTV viremia is common in CSAI but shows no significant association with inflammation or short‐term outcomes, suggesting limited value for risk stratification.
1 August 1995 in Electroencephalography and Clinical Neurophysiology